Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Ponesimod in Healthy Males
NCT02068235Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ponesimod in multiple sclerosis (MS) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area under the plasma concentration-time curve from time zero to 144 hours, Area under the plasma concentration-time curve from time zero to infinity at 7 Days and 6 more. Started Aug 2014; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02068235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068235.